BTK Inhibitor Combinations Move to Forefront of CLL Investigations, Conversations

Mazyar Shadman, MD, MPH, details the efficacy of BTK inhibitors in the frontline treatment of CLL as well as safety considerations in the relapsed/refractory setting.

Related Keywords

United States ,Washington ,North Carolina ,Switzerland ,Lugano ,Ticino ,University Of Washington ,Seattle ,American ,Alan Skarbnik ,Mazyar Shadman ,American Society Of Hematology Annual Meeting Exposition ,Novant Health In Charlotte ,International Conference On Malignant Lymphoma ,Oncology Division ,University Of Washington School Medicine ,Innovators Network ,Onclive Scientific Interchange ,Workshop Chronic Lymphocytic Leukemia ,Latest Data ,Clinical Practice ,Innovators Network Endowed Chair ,Clinical Research Division ,Fred Hutch Cancer Center ,Medical Oncology Division ,Washington School ,Shows Efficacy ,Novant Health ,American Society ,Hematology Annual Meeting ,Safety Considerations With ,Noncovalent Inhibition With ,International Conference ,Malignant Lymphoma ,